Please assess the completion status of the following clinical trial:

Trial Title: Adoptive Cell Therapy Across Cancer Diagnoses

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Only patients within the Danish Healthcare system are eligible for enrollment.~Inclusion Criteria:~* Histologically verified metastatic or locally advanced cancer diagnosis~* At least one lesion (\>1 cm3) available for surgical resection~* Not candidate for standard treatment options~* Age of 18-70 years~* Performance status of 1 or 0.~* Life expectancy \> 6 months~* One or more measurable parameter according to RECIST 1.1.~* No significant toxicity from previous cancer treatments (CTC≤1). Except alopecia (CTC≤2) or neuropathy (CTC≤2)~* Sufficient organ function, including:~* Absolute neutrophil count (ANC) ≥ 1.500 /µl~* Leucocyte count ≥ normal limit~* Platelets ≥ 100.000 /µl and \<700.000 /µl~* Hemoglobin ≥ 6,0 mmol/l (regardless of prior transfusion)~* S-creatinine \< 140~* S-bilirubin ≤ 1,5 times upper normal limit~* ASAT/ALAT ≤ 2,5 times upper normal limit~* Alkaline phosphatase ≤ 5 times upper normal limit~* Lactate dehydrogenase (LDH) ≤ 5 times upper normal limit~* Sufficient coagulation: PP-time\>40 and INR\<1,5~* Women in the fertile age must use effective contraception. This applies from inclusion and until 6 months after treatment. Birth control pills, spiral, depot injection with gestagen, subdermal implantation, hormonal vaginal ring and transdermal depot patch are all considered safe contraceptives.~* Signed statement of consent after receiving oral and written study information~* Willingness to participate in the planned treatment and follow-up and capable of handling toxicities.~Exclusion Criteria:~* A history of prior malignancies. Patients treated for another malignancy can only participate if they are without signs of disease for a minimum of 3 years after last treatment.~* Primary brain tumor or verified brain metastases~* Known hypersensitivity to one of the active drugs or excipients.~* Significant medical conditions, including but not limited to severe asthma/COLD, significant cardiac disease, poorly regulated insulin dependent diabetes mellitus.~* Creatinine clearance below 70 ml/min .~* Acute or chronic infections with HIV, hepatitis, syphilis etc.~* Severe allergies or previous anaphylactic reactions.~* Active autoimmune disease, such as autoimmune neutropenia/thrombocytopenia or hemolytic anemia, systemic lupus erythematosus, Sjögren's syndrome, sclerodermia, myasthenia gravis, goodpastures disease, addison's disease, hashimoto's thyroiditis, graves' disease etc.~* Pregnant women and women who are breastfeeding.~* Simultaneous treatment with systemic immunosuppressive drugs (including prednisolone methotrexate etc.)~* Simultaneous treatment with other experimental drugs.~* Simultaneous treatment with other systemic anti-cancer treatments.~* Patients with active or uncontrollable hypercalcemia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Tumor-infiltrating Lymphocyte (TIL) Therapy with checkpoint inhibitors (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).